InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain

Revista Española De Cardiología
Marcelo SotoJosep Brugada-Terradellas

Abstract

In Spain, 0.3% of patients with hypertension are refractory to conventional treatment. The complications resulting from deficient control of this condition can lead to poor quality of life for the patient and considerable health care costs. Barostim is an implantable device designed to lower blood pressure in these patients. The aim of this study was to analyze the cost-effectiveness of Barostim compared with drug therapy in hypertensive patients refractory to conventional treatment (at least 3 antihypertensive drugs, including 1 diuretic agent). We used a Markov model adapted to the epidemiology of the Spanish population to simulate the natural history of a cohort of patients with refractory hypertension over their lifetime. Data on the effectiveness of the treatments studied were obtained from the literature, and data on costs were taken from hospital administrative databases and official sources. Deterministic and probabilistic sensitivity analyses were conducted. Barostim increased the number of quality-adjusted life years by 0.78 and reduced the number of hypertension-associated clinical events. The incremental cost-effectiveness ratio in a cohort of men reached 68 726 euros per year of quality-adjusted life. One of the ma...Continue Reading

References

Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
Jan 1, 1994·Stroke; a Journal of Cerebral Circulation·R B D'AgostinoW B Kannel
Jun 1, 1993·Stroke; a Journal of Cerebral Circulation·M S DennisC P Warlow
May 29, 1998·Circulation·P W WilsonW B Kannel
Jun 17, 1999·Archives of Internal Medicine·W B KannelD Levy
Jun 5, 2002·The Journal of Clinical Hypertension·J D SteinH D Stein
Mar 12, 2003·Circulation·J Malcolm O ArnoldUNKNOWN HOPE Investigators
Jun 17, 2003·PharmacoEconomics·Emile LevyJérôme Dinet
Sep 8, 2004·European Journal of Cardiovascular Nursing : Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology·E Anne LaceyPeter Scott
Sep 30, 2005·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Louise LongworthDavid H Smith
Nov 26, 2005·Current Medical Research and Opinion·Amanda J LeeCraig J Currie
Mar 28, 2006·The American Journal of Medicine·Brandi J WittVéronique L Roger
Jun 22, 2007·Journal of the American Society of Nephrology : JASN·Emmanuel VillarRené Ecochard
Aug 7, 2007·Journal of Cardiac Failure·Brandi J WittVéronique L Roger
Oct 29, 2008·Circulation·Raghava S VelagaletiRamachandran S Vasan
Mar 11, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Milton C WeinsteinAlistair McGuire
Aug 20, 2009·JAMA : the Journal of the American Medical Association·Harlan M KrumholzSharon-Lise T Normand
Nov 18, 2011·JAMA : the Journal of the American Medical Association·Bruce OvbiageleUNKNOWN PROFESS Investigators
Sep 4, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·A Simon PickardJames W Shaw
Oct 19, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Daisaku NakataniUNKNOWN Osaka Acute Coronary Insufficiency Study (OACIS) Investigators
Apr 27, 2013·Journal of the American Society of Nephrology : JASN·Anne M MurrayCraig A Solid
Jan 15, 2014·Preventive Medicine·Jaume MarrugatUNKNOWN FRESCO Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.